**Growth hormone-secreting pituitary adenoma with gigantism: A challenging case**

Amish Chinoi MRCPCH¹; Dunia Ismail MD¹; Jennifer Kalitsi RNC²; Nadia Gordon RNC⁴; Peter Bullock FRCS⁵; Ritika R Kapoor MD, PhD⁶; Simon JB Aylwin MD, FRCP, Phd⁶ & Charles R Buchanan FRCPCH²

Royal Alexandra Children’s Hospital, Brighton, UK¹; Dept Child Health, King’s College Hospital, London, UK²; Dept Endocrinology, King’s College Hospital, London, UK³; Neurosurgery, King’s College Hospital, London, UK⁴

*Interests & Funding: CRB has been supported to attend ESPE 2014 by educational travel grant from MerckSerono; JK is being supported to attend ESPE 2014 by Ferring Pharmaceuticals*

**Introduction:**

Pituitary gigantism is a rare condition arising from excessive secretion of growth hormone (GH) during childhood, usually associated with a pituitary micro- or macro-adenoma and sometimes with specific gene mutations which predispose to these (1). Successful treatment goals include limiting final height attainment as well as normalisation of GH to prevent future development of acromegaly and co-morbidities, definitive tumour control, and replacement of any pituitary hormone deficiencies. We present a case requiring the full spectrum of therapeutic options.

**Case Report:**

**History:** A 15 yr old boy presented with 3 yr history of intractable occipital headache and complaint of rapid, excessive growth during puberty. He was psychologically distressed by his height of 203cm, and how his tall stature had impact on social relationships and daily lifestyle. He had mild clinical features (facial) suggestive of GH excess. Pubertal development was age appropriate. Bone age not advanced. No visual deficit.

**Investigations:**

- **Serum IGF-I**: 103 nmol/L (RR 13-66)
- **Testosterone**: 3.7 nmol/L (low for pubertal status)
- **Cortisol response to Synacthen (250mcg IV)** was impaired,
  - 60: 19.2 mg/dL,
  - 90: 14.9 mg/dL

**MRI pituitary** revealed a pituitary macroadenoma (18mm x 18mm x 22mm), impinging from below on the posterior aspect of the optic chiasm, with lateral invasion of left cavernous sinus (see image far right).

**GH** was partially suppressed by **Octreotide (100mcg)** from 50 to 25 mcg/L by 6 hrs, and possibly better suppression observed with **Pasireotide (600 mcg)** from 28 to 8 mcg/L by 6 hrs (see tables). **Pituitary MRI at presentation**

**Outcome:**
- **Headaches improved.**
- **Visual fields normalised.**
- **Post-op. Oral Glucose load showed basal GH 3 mcg/l without suppression** – see table.

**Radiotherapy** to control residual tumour was offered, but the patient declined at that stage, wishing to focus on a return to his academic studies with a view to radiotherapy after current academic year, unless changed clinical circumstances led to reconsider that plan. However, interval MRI scan after 4 months (images to left) showed significant increase in residual adenoma and the patient has since undergone standard photon 47 Gy radiotherapy in 25# over 5 weeks, completed April 2014.

**Further Medical Treatment**
- **Patient profoundly disliked the taste of Hydrocortisone** – this has been substituted with Prednisolone once daily.
- **Compliance with Pegvisomant was increasingly poor** (see rising IGF-I levels).
- **Consideration is being given to introduce Pasireotide treatment which will** potentially be better tolerated than Pegvisomant as a monthly injection, and may prove to be more effective than Octreotide (see test dose responses and refs 2 and 3 – the latter suggesting that Pasireotide may be more effective in patients with gigantism who harbour mutations in the AIP gene).
- **Genetic studies are underway.**
- **Psychological support is being provided to help the patient and his mother.**
- **Latest MRI shows possible reduction in pituitary size,** though it was too soon after radiotherapy to appreciate full effects. Further MRI scan is booked for December 2014.

**References**